2 completed, 2 unknown, 1 recruiting. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Unknown 2, Recruiting 1 |
Follow PharmAbcine: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 PMC-309 monotherapy, PMC-309 Dose Escalation in Combination with Pembrolizumab(KEYTRUDA®), PMC-309 Dose Expansion - Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | PharmAbcine | 67 | 2024-01-03 | 2025-12-30 |
| Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration PMC-403 - Neovascular Age-related Macular Degeneration | Phase 1 | Completed | PharmAbcine | 17 | 2023-07-20 | 2025-12-30 |
| TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma TTAC-0001 and pembrolizumab combination - Recurrent Glioblastoma | Phase 1 | Unknown | PharmAbcine | 9 | 2019-01-16 | 2022-08-17 |
| TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer TTAC-0001 and pembrolizumab combination - Triple Negative Breast Cancer | Phase 1 | Unknown | PharmAbcine | 11 | 2019-01-03 | 2022-08-17 |
| Phase I Trial of Tanibirumab in Advanced or Metastatic Cancer Tanibirumab - Advanced Cancer, Metastatic Cancer | Phase 1 | Completed | PharmAbcine | 26 | 2011-11-01 | 2014-01-29 |
Glioblastoma (1) · Neoplasm Metastasis (1) · Triple Negative Breast Neoplasms (1)
olinvacimab (3) · Combined Modality Therapy (1)
Australia (3) · South Korea (2)
Andrea Tazbirkova, Dr (1) · SeJoon Woo (1) · Young Seok Park, MD, PhD (1)